
Extended INDIGO and FIREFLY-1 results presented at SNO 2026 put seizure burden during vorasidenib therapy and time off tovorafenib in pediatric low-grade glioma into focus.
Oxcarbazepine Oral Suspension, USP 300 mg/5 mL is available in 250 mL bottles.
Camber Pharmaceuticals is pleased to announce the addition of Oxcarbazepine Oral Suspension, USP to its current portfolio.
Oxcarbazepine Oral Suspension, USP is indicated for:
Oxcarbazepine Oral Suspension, USP 300 mg/5 mL is available in 250 mL bottles.
To find out more about Oxcarbazepine Oral Suspension, USP, please visit






